The consequences of Smad3 deletion have been previously examined in several animal models of cardiovascular diseases (21, 78–81), but to our knowledge, this is the first evaluation of the role of this transcription factor in cardiac injury by doxorubicin. Here, SMAD3 is linked to cardiovascular disorder.